Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
Key facts
- Who runs it
- Clinuvel, Inc.
- Where
- Alpharetta, Augusta, Baton Rouge, Birmingham, Cedar Park, Charleston, Charlottesville, Chicago, Cleveland, Dallas, Detroit, Fresno, Lee's Summit, Los Angeles, Miami, Minneapolis, Miramar, Palo Alto, Philadelphia, Rochester, Roseville, San Diego, Thompson's Station, Tyler, and Washington D.C., United StatesSee the 25 sitesAlso in 4 other countries, 6 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 200 people, planned
- Started
- 11 Oct 2023
- Ended
- Jun 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Afamelanotide and NB-UVB Light
- NB-UVB Light
- Record updated
- 8 July 2025
Who can take part
- Age
- 12 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Male and female patients with a confirmed diagnosis of generalized vitiligo with VASI≥3 of the body and VASI on the head and neck ≥0.3 including an F-VASI≥0.1
- Stable or active vitiligo
- Aged 12 or more
- Fitzpatrick skin types III-VI
Who cannot take part
- Treatment with NB-UVB phototherapy in the last three months prior to study start
- Any other treatment for vitiligo within 30 days prior to the Screening Visit
- Use of any prior and concomitant therapy which may interfere with the objective of the study
- Allergy to afamelanotide or the polymer contained in the implant
- History of melanoma or lentigo maligna
- History of dysplastic nevus syndrome
- Any malignant skin lesions
- Presence of severe hepatic disease or hepatic impairment
- Fitzpatrick skin types I-II
- Extensive leukotrichia
- Female who is pregnant or lactating
- Female of child-bearing potential not using adequate contraceptive measures
- Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures
- Extensive tattoos
Where in United States
Also in 4 other countries, 6 sites
- Alpharetta, GeorgiaHospital not named in the registry
- Augusta, GeorgiaHospital not named in the registry
- Baton Rouge, LouisianaHospital not named in the registry
- Birmingham, AlabamaHospital not named in the registry
- Cedar Park, TexasHospital not named in the registry
- Charleston, South CarolinaHospital not named in the registry
- Charlottesville, VirginiaHospital not named in the registry
- Chicago, IllinoisHospital not named in the registry
- Cleveland, OhioHospital not named in the registry
- Dallas, TexasHospital not named in the registry
- Detroit, MichiganHospital not named in the registry
- Fresno, CaliforniaHospital not named in the registry
- Lee's Summit, MissouriHospital not named in the registry
- Los Angeles, CaliforniaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Minneapolis, MinnesotaHospital not named in the registry
- Miramar, FloridaHospital not named in the registry
- Palo Alto, CaliforniaHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- Rochester, New YorkHospital not named in the registry
- Roseville, MinnesotaHospital not named in the registry
- San Diego, CaliforniaHospital not named in the registry
- Thompson's Station, TennesseeHospital not named in the registry
- Tyler, TexasHospital not named in the registry
- Washington D.C., District of ColumbiaHospital not named in the registry
About the trial
What the trial wants to find out
The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.
The 2 groups in the trial
- Afamelanotide and NB-UVB LightTreatment being tested
- NB-UVB LightOther group
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo
- Record updated
- 8 July 2025